ProQR Therapeutics (NASDAQ:PRQR) Lowered to Sell at StockNews.com

StockNews.com cut shares of ProQR Therapeutics (NASDAQ:PRQR) from a hold rating to a sell rating in a research note released on Friday morning.

Several other brokerages have also issued reports on PRQR. HC Wainwright reissued a buy rating and set a $5.00 target price on shares of ProQR Therapeutics in a research note on Friday, May 10th. Chardan Capital restated a buy rating and issued a $2.50 target price on shares of ProQR Therapeutics in a research note on Friday, May 10th. Finally, Citigroup upped their price target on ProQR Therapeutics from $1.80 to $2.00 and gave the stock a buy rating in a research note on Thursday, April 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $3.38.

ProQR Therapeutics Price Performance

Shares of NASDAQ:PRQR opened at $1.71 on Friday. ProQR Therapeutics has a 1 year low of $1.11 and a 1 year high of $3.29. The business’s 50-day moving average is $1.91 and its 200-day moving average is $2.05. The company has a market capitalization of $139.13 million, a price-to-earnings ratio of -4.62 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The firm had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.31 million. ProQR Therapeutics had a negative return on equity of 61.58% and a negative net margin of 260.75%. Analysts anticipate that ProQR Therapeutics will post -0.37 EPS for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RFG Advisory LLC bought a new stake in ProQR Therapeutics during the 1st quarter worth approximately $73,000. BNP Paribas Financial Markets grew its holdings in ProQR Therapeutics by 120.1% during the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 19,100 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in ProQR Therapeutics in the 1st quarter valued at $56,000. EP Wealth Advisors LLC bought a new position in ProQR Therapeutics during the 1st quarter valued at $26,000. Finally, Ikarian Capital LLC boosted its holdings in ProQR Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock worth $1,098,000 after acquiring an additional 10,958 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).